Detalles de la búsqueda
1.
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
J Hepatol
; 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38583491
2.
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
Gut
; 72(7): 1385-1398, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36697207
3.
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.
J Antimicrob Chemother
; 77(4): 1102-1110, 2022 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35040959
4.
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Gastroenterology
; 159(2): 521-533.e9, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32343960
5.
Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro.
J Antimicrob Chemother
; 75(9): 2526-2534, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32417895
6.
Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy.
J Viral Hepat
; 27(11): 1127-1137, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32579776
7.
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
Virol J
; 15(1): 26, 2018 01 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29378602
8.
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Transpl Infect Dis
; 19(3)2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28295849
9.
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
J Gastroenterol Hepatol
; 31(5): 912-20, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26777137
10.
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
J Hepatol
; 62(5): 1008-14, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25445400
11.
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
Antimicrob Agents Chemother
; 59(12): 7548-57, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26392483
12.
Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.
Gastroenterology
; 143(5): 1176-1178.e6, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22885330
13.
Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study.
Antiviral Res
; 216: 105660, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37385475
14.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Lancet Gastroenterol Hepatol
; 8(9): 790-802, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37442152
15.
Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
J Antimicrob Chemother
; 67(10): 2327-37, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22723600
16.
Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.
J Virol
; 84(21): 11124-33, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20739521
17.
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Antimicrob Agents Chemother
; 54(5): 1878-87, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20176898
18.
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
Antimicrob Agents Chemother
; 53(4): 1377-85, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19171797
19.
Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro.
Antiviral Res
; 144: 205-215, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28647474
20.
Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.
Open Forum Infect Dis
; 3(2): ofw052, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27186579